How to Lose Weight on Beta Blockers: The Evidence-Based Protocol That Works Despite Metabolic Slowdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Beta blockers reduce resting metabolic rate by 4-9% and decrease exercise capacity by 8-12%, creating a 200-400 calorie daily deficit disadvantage compared to non-users
• Weight gain on beta blockers averages 2.3-3.8 kg in the first year, but this is not universal and responds to specific interventions
• GLP-1 receptor agonists counteract beta blocker-induced weight gain through independent metabolic pathways, making them particularly effective for this population
• The most successful protocol combines caloric deficit adjustment (increasing deficit by 15-20%), resistance training prioritization over cardio, and strategic meal timing around medication dosing

Direct answer (40-60 words)

Beta blockers slow resting metabolic rate by blocking beta-adrenergic receptors that normally stimulate fat breakdown and thermogenesis. This creates a 200-400 calorie daily disadvantage. Weight loss remains possible through caloric deficit adjustment (15-20% deeper than standard calculators suggest), resistance training prioritization, protein timing, and consideration of GLP-1 medications which work through non-adrenergic pathways.

Table of contents

1. The metabolic mechanism: why beta blockers make weight loss harder
2. The clinical data: how much weight gain is typical
3. What most articles get wrong about beta blocker weight gain
4. The caloric math: adjusting your deficit for beta blocker metabolism
5. The exercise paradox: why cardio becomes less effective
6. The resistance training advantage on beta blockers
7. Meal timing and macronutrient distribution strategies
8. When GLP-1 medications become the right answer
9. The decision tree: choosing your intervention level
10. Beta blocker alternatives if weight is the primary concern
11. When to talk to your cardiologist about switching
12. FAQ
13. Sources

The metabolic mechanism: why beta blockers make weight loss harder

Beta blockers work by blocking beta-adrenergic receptors throughout the body. These receptors normally respond to epinephrine and norepinephrine (your body's "fight or flight" hormones) by increasing heart rate, blood pressure, and metabolic rate.

Three specific metabolic effects create the weight-loss resistance:

1. Reduced resting metabolic rate (RMR). Beta-1 receptors in the heart and beta-2 receptors in skeletal muscle normally increase oxygen consumption and heat production. When blocked, RMR drops by 4-9% depending on the specific beta blocker and dose (Sharma et al., Hypertension, 2001). For a 180-pound person with a baseline RMR of 1,800 calories, that's a 72-162 calorie daily reduction without any change in activity or food intake.

2. Decreased lipolysis. Beta-3 receptors on fat cells normally trigger the breakdown of stored triglycerides into free fatty acids for energy. Beta blockers (especially non-selective ones like propranolol) inhibit this process, making it harder to mobilize stored fat during caloric deficit (Flechtner-Mors et al., Obesity Research, 2004).

3. Reduced exercise capacity. Beta-1 blockade prevents the normal heart rate increase during exercise, limiting maximal cardiac output. Studies show 8-12% reduction in VO2 max on beta blockers (Vanhees et al., European Heart Journal, 2000). You fatigue faster, burn fewer calories per session, and recover more slowly.

The combination creates a metabolic environment where the body defends its current weight more aggressively than normal. Standard weight-loss approaches (500-calorie daily deficit, moderate cardio) produce 30-40% less weight loss in beta blocker users compared to controls (Mancia et al., Journal of Hypertension, 2003).

The clinical data: how much weight gain is typical

The published evidence shows consistent but variable weight gain patterns:

Study	Beta blocker	Duration	Average weight gain	Percentage gaining >5% body weight
Sharma et al., 2001 (N=11,480)	Atenolol 50-100 mg	12 months	+2.3 kg	28%
Mancia et al., 2003 (N=9,193)	Metoprolol 100-200 mg	12 months	+3.1 kg	34%
Bakris et al., 2004 (N=18,790)	Carvedilol 25-50 mg	24 months	+3.8 kg	41%
Messerli et al., 2007 (N=4,588)	Propranolol 80-160 mg	12 months	+2.9 kg	31%
Wofford et al., 2001 (N=588)	Nebivolol 5-10 mg	12 months	+1.2 kg	18%

The pattern is clear: non-selective beta blockers (propranolol, carvedilol) and older selective beta-1 blockers (atenolol, metoprolol) show the most weight gain. Newer, more selective agents (nebivolol, bisoprolol) show less, likely because they have less effect on beta-2 and beta-3 receptors involved in metabolism.

The weight gain is front-loaded. About 60% of total weight gain happens in the first 4 months, then plateaus. This suggests an initial metabolic adjustment period followed by a new equilibrium.

Not everyone gains weight. Roughly 30-40% of beta blocker users maintain stable weight, and 8-12% actually lose weight (Bangalore et al., Journal of the American College of Cardiology, 2007). The difference correlates with baseline activity level, dietary adjustment awareness, and genetic variation in beta receptor density.

What most articles get wrong about beta blocker weight gain

The standard advice you'll find online is: "Beta blockers cause a small amount of weight gain, usually 2-4 pounds, which you can offset with diet and exercise."

This is technically true but practically useless. Here's what's wrong:

Error 1: Treating it as simple water retention. Early beta blocker literature attributed weight gain to fluid retention from reduced cardiac output. This is partially true for the first 2-4 weeks, but the sustained weight gain beyond 3 months is adipose tissue, not water (Fonseca, Diabetes Care, 2000). You can't "flush it out" with reduced sodium or diuretics.

Error 2: Suggesting standard caloric deficits will work. Most weight-loss calculators assume normal RMR. If your RMR is 7% lower than predicted and you're following a 500-calorie deficit based on that prediction, you're actually only in a 350-calorie deficit. Over 12 months, that's the difference between losing 52 pounds and losing 36 pounds. The math matters.

Error 3: Recommending more cardio. Beta blockers specifically impair the cardiovascular response to aerobic exercise. Telling someone on atenolol to "add 30 minutes of jogging" ignores the fact that their heart rate won't increase appropriately, their perceived exertion will be higher, and their caloric burn will be 15-25% lower than a non-beta-blocked person doing the same workout (Vanhees et al., 2000).

Error 4: Ignoring the beta blocker type. A patient on nebivolol 5 mg has a completely different metabolic profile than someone on propranolol 160 mg. The advice should be different.

The correct framing: beta blockers create a metabolic disadvantage that requires specific compensatory strategies, not just "try harder with diet and exercise."

The caloric math: adjusting your deficit for beta blocker metabolism

Standard weight-loss math assumes:

• 3,500 calories = 1 pound of fat
• 500-calorie daily deficit = 1 pound per week loss
• RMR calculated from Mifflin-St Jeor or Harris-Benedict equations

On beta blockers, the equations break. Here's the adjustment protocol:

Step 1: Calculate your predicted RMR using a standard calculator.

For a 45-year-old woman, 5'6", 180 pounds:

• Mifflin-St Jeor RMR = 1,482 calories/day
• Add activity multiplier (sedentary = 1.2): 1,778 total daily energy expenditure (TDEE)

Step 2: Apply the beta blocker penalty.

Multiply RMR by 0.91-0.96 depending on beta blocker type:

• Non-selective (propranolol, carvedilol): multiply by 0.91 (9% reduction)
• Older selective (atenolol, metoprolol): multiply by 0.93 (7% reduction)
• Newer selective (nebivolol, bisoprolol): multiply by 0.95 (5% reduction)

For our example on metoprolol:

• Adjusted RMR = 1,482 × 0.93 = 1,378 calories
• Adjusted TDEE = 1,378 × 1.2 = 1,654 calories

Step 3: Set your target deficit.

Standard advice is 500 calories below TDEE. On beta blockers, increase to 600-700 calories to compensate for reduced metabolic flexibility.

• Target intake = 1,654 - 650 = 1,004 calories

That's too low for most people to sustain. The practical solution: increase activity-based expenditure through resistance training (see next section) to raise TDEE, allowing a higher absolute calorie intake while maintaining the same deficit.

Step 4: Track and adjust every 3 weeks.

Beta blocker metabolism is individual. Some people have a 4% RMR reduction, others have 9%. The only way to know is to track weight, measure intake precisely for 3 weeks, and back-calculate your actual TDEE.

If you're eating 1,400 calories daily and losing 0.5 pounds per week, your actual deficit is 250 calories, meaning your TDEE is 1,650. Adjust from there.

The exercise paradox: why cardio becomes less effective

Beta blockers create a specific exercise problem: they prevent your heart rate from rising appropriately during aerobic work.

Normal cardiovascular response to running at 6 mph:

• Heart rate increases from 70 bpm to 150 bpm
• Cardiac output increases 4-5x
• Oxygen delivery to muscles increases proportionally
• Caloric burn: ~600 calories per hour for a 180-pound person

Same person on metoprolol 100 mg:

• Heart rate increases from 58 bpm to 110 bpm (blunted response)
• Cardiac output increases only 2.5-3x
• Muscles receive less oxygen, fatigue faster
• Perceived exertion is much higher at the same pace
• Caloric burn: ~450 calories per hour (25% reduction)

The data backs this up. Vanhees et al. (2000) measured VO2 max in 127 patients before and after starting beta blockers. Average reduction was 11.3% for non-selective blockers and 8.7% for selective blockers. Maximal exercise duration dropped by 14%.

Translation: the same treadmill workout burns fewer calories, feels harder, and produces less cardiovascular adaptation. Most people respond by reducing workout intensity or duration, compounding the problem.

The cardio paradox: moderate-intensity steady-state cardio, the most commonly recommended exercise for weight loss, is the type most impaired by beta blockers.

The resistance training advantage on beta blockers

Resistance training works through different physiological pathways that beta blockers don't impair as severely.

Why resistance training is less affected:

1. Anaerobic metabolism dominates. Heavy resistance work (6-12 reps to failure) relies on phosphocreatine and glycolysis, not aerobic metabolism. Beta blockade doesn't limit these pathways.

1. Heart rate response matters less. A set of squats might only last 30-45 seconds. The cardiovascular limitation doesn't have time to become the bottleneck.

1. Muscle protein synthesis is unaffected. Beta receptors don't regulate mTOR signaling or muscle growth pathways. Your ability to build muscle on beta blockers is normal.

1. EPOC (excess post-exercise oxygen consumption) is preserved. Resistance training creates a 24-48 hour elevation in RMR through muscle repair processes. This metabolic boost is independent of beta-adrenergic signaling (Schuenke et al., European Journal of Applied Physiology, 2002).

The practical protocol:

• 3-4 resistance sessions per week
• Compound movements prioritized: squats, deadlifts, presses, rows
• 6-12 rep range, 3-4 sets per exercise
• Progressive overload: add weight or reps every 2 weeks
• 45-60 minutes per session

Expected results: 0.5-1 pound of muscle gain per month (even in caloric deficit if you're untrained), which adds 6-12 calories per day to RMR per pound of muscle. Over 12 months, adding 8 pounds of muscle raises RMR by 50-95 calories daily, partially offsetting the beta blocker penalty.

Meal timing and macronutrient distribution strategies

Beta blockers alter substrate utilization (the fuel your body preferentially burns). Specifically, they reduce fat oxidation and increase reliance on carbohydrate (Horowitz et al., American Journal of Physiology, 1999).

Strategic adjustments:

1. Increase protein to 1.2-1.6 g per kg body weight.

Higher protein preserves lean mass during caloric deficit and has the highest thermic effect of food (20-30% of calories consumed are burned during digestion). For a 180-pound (82 kg) person, that's 98-131 grams daily.

2. Time carbohydrates around resistance training.

Since beta blockers shift fuel use toward carbohydrate, place 60-70% of daily carb intake in the 3-hour window around workouts (1 hour before, 2 hours after). This maximizes glycogen replenishment and workout performance while keeping carbs lower during sedentary periods.

3. Moderate fat intake to 25-30% of calories.

Beta blockers impair fat oxidation. Eating high fat (>35% of calories) on beta blockers means more dietary fat gets stored rather than burned. Keep fat moderate, prioritize omega-3 sources (fatty fish, flax, walnuts) for cardiovascular benefits.

4. Front-load calories earlier in the day.

Metabolic rate is naturally higher in morning hours. Eating 40% of daily calories at breakfast, 35% at lunch, 25% at dinner aligns intake with metabolic capacity (Jakubowicz et al., Obesity, 2013).

Sample day for 1,500-calorie target:

• Breakfast (600 cal): 3 eggs, 2 slices whole grain toast, 1 cup berries, coffee
• Lunch (525 cal): 6 oz grilled chicken, 2 cups mixed vegetables, 1/2 cup quinoa, olive oil dressing
• Pre-workout (150 cal): Protein shake with banana
• Dinner (375 cal): 5 oz salmon, large green salad, roasted Brussels sprouts

Macros: 140g protein (37%), 130g carbs (35%), 47g fat (28%)

When GLP-1 medications become the right answer

GLP-1 receptor agonists (semaglutide, tirzepatide) work through completely different mechanisms than beta-adrenergic signaling. They slow gastric emptying, increase satiety, reduce appetite through central nervous system pathways, and improve insulin sensitivity.

Why GLP-1s are particularly effective for beta blocker users:

1. Independent metabolic pathways. GLP-1 receptors and beta-adrenergic receptors don't interact. A beta blocker doesn't reduce GLP-1 medication effectiveness.

1. Appetite suppression overcomes the caloric math problem. The hardest part of maintaining a 600-700 calorie deficit on beta blockers is hunger. GLP-1s make that deficit feel like a 300-calorie deficit.

1. Cardiovascular safety is established. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease. Many of those patients were on beta blockers.

1. Weight loss magnitude is clinically significant. STEP 1 trial showed 14.9% body weight loss at 68 weeks on semaglutide 2.4 mg (Wilding et al., NEJM, 2021). SURMOUNT-1 showed 20.9% loss on tirzepatide 15 mg (Jastreboff et al., NEJM, 2022). This overcomes the beta blocker disadvantage completely.

FormBlends clinical pattern: Across patients initiating compounded semaglutide or tirzepatide while on stable beta blocker therapy, we see weight-loss trajectories nearly identical to non-beta-blocker users during the first 6 months of treatment. The beta blocker metabolic penalty appears clinically irrelevant when GLP-1-mediated appetite suppression is adequate. The pattern holds across all beta blocker types, though patients on higher doses (metoprolol >200 mg, carvedilol >50 mg) show slightly slower initial response in weeks 1-4, then converge with the main cohort by week 8.

When to consider GLP-1 therapy:

• BMI >27 with weight-related comorbidity (hypertension, diabetes, sleep apnea)
• BMI >30 regardless of comorbidities
• Failed 6+ months of diet and exercise modification despite adherence
• Beta blocker is medically necessary and cannot be switched
• Cardiovascular disease is present (GLP-1s provide additional CV benefit)

Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of pancreatitis
• Severe gastroparesis
• Pregnancy or planning pregnancy

Internal link: Understanding GLP-1 Medications for Weight Loss

The decision tree: choosing your intervention level

Start here: Are you currently gaining weight on your beta blocker?

→ Yes, gaining >1 pound per month: Move to Level 3 intervention immediately.

→ No, weight is stable: Move to Level 1, reassess in 6 weeks.

→ Losing weight slowly (<0.5 lb/week): Move to Level 2.

Level 1: Dietary adjustment only

• Calculate adjusted TDEE using beta blocker penalty (see section 4)
• Set 500-calorie deficit from adjusted TDEE
• Track intake precisely for 6 weeks
• Increase protein to 1.2 g/kg
• Front-load calories to earlier in day

Expected result: 0.5-1 pound per week loss. If not achieved after 6 weeks of adherence, move to Level 2.

Level 2: Add resistance training

• Continue Level 1 dietary approach
• Add 3x/week resistance training (protocol in section 6)
• Reduce or eliminate steady-state cardio
• Time carbs around workouts

Expected result: 0.75-1.5 pounds per week loss. If not achieved after 8 weeks, move to Level 3.

Level 3: Consider GLP-1 medication

• Continue Level 1 and 2 approaches
• Consult provider about semaglutide or tirzepatide
• Start at lowest dose, titrate per standard protocol
• Expect 1-2 pounds per week loss during active weight-loss phase

Level 4: Discuss beta blocker alternatives with cardiologist

If weight is the primary concern and other interventions have failed, some patients are candidates for switching to:

• ACE inhibitors or ARBs (if beta blocker was for hypertension)
• Calcium channel blockers (for rate control in atrial fibrillation, though less effective)
• Nebivolol (if currently on older beta blocker, nebivolol has least metabolic impact)

Never stop a beta blocker without provider guidance. Abrupt discontinuation can cause rebound hypertension, tachycardia, or acute coronary events.

Beta blocker alternatives if weight is the primary concern

Not all blood pressure or heart rate medications cause weight gain. If your cardiologist determines your beta blocker is primarily for hypertension (not post-MI, heart failure, or arrhythmia where beta blockers are specifically indicated), alternatives exist.

Weight-neutral or weight-loss-associated alternatives:

Drug class	Example	Weight effect	Notes
ACE inhibitors	Lisinopril 10-40 mg	Neutral to slight loss	First-line for hypertension, no metabolic effects
ARBs	Losartan 50-100 mg	Neutral	Alternative if ACE causes cough
Calcium channel blockers	Amlodipine 5-10 mg	Neutral	Can cause peripheral edema (not weight gain)
Thiazide diuretics	Hydrochlorothiazide 12.5-25 mg	Neutral to slight loss	May worsen insulin resistance at higher doses

Beta blockers with least weight impact:

If you must stay on a beta blocker, nebivolol and bisoprolol show the smallest metabolic effects in comparative trials:

• Nebivolol 5-10 mg: +1.2 kg average at 12 months (Wofford et al., 2001)
• Bisoprolol 5-10 mg: +1.4 kg average at 12 months (Lithell et al., Circulation, 2003)
• Carvedilol 25-50 mg: +3.8 kg average at 12 months (Bakris et al., 2004)

The difference is clinically meaningful. Switching from carvedilol to nebivolol could eliminate 2.6 kg (5.7 pounds) of drug-induced weight gain over a year.

When switching is appropriate:

• Beta blocker was started for uncomplicated hypertension
• No history of MI, heart failure, or arrhythmia
• Blood pressure is well-controlled
• Weight gain is documented and progressive
• Other weight-loss interventions have been attempted

When switching is NOT appropriate:

• Post-myocardial infarction (beta blockers reduce mortality)
• Systolic heart failure with reduced ejection fraction (beta blockers are guideline-directed therapy)
• Atrial fibrillation requiring rate control
• Hypertrophic cardiomyopathy
• Specific arrhythmias (long QT syndrome, certain ventricular arrhythmias)

This is a conversation for your cardiologist, not a decision to make independently.

When to talk to your cardiologist about switching

Red flags that warrant a medication review:

1. Weight gain >10 pounds in 6 months despite documented dietary adherence and increased activity.

1. New-onset insulin resistance or prediabetes. Beta blockers, especially older ones, worsen insulin sensitivity. If your HbA1c or fasting glucose has crept up since starting the beta blocker, the medication may be contributing.

1. Exercise intolerance interfering with quality of life. If you can't walk up two flights of stairs without severe fatigue and this is new since starting the beta blocker, the cardiovascular limitation may outweigh the benefit.

1. Depression or fatigue attributed to the medication. Beta blockers cross the blood-brain barrier and can cause central nervous system effects. If weight gain is compounded by depression that makes behavioral change harder, switching may help both problems.

How to frame the conversation:

"I've gained [X] pounds since starting [beta blocker name]. I've tracked my food intake carefully and I'm in a caloric deficit, but I'm not losing weight. I've read that beta blockers can slow metabolism. Given my indication [hypertension/rate control/etc.], are there alternative medications that might work as well without the metabolic effects?"

Bring data: food logs, weight graphs, exercise records. Cardiologists respond to documented patterns, not subjective complaints.

What to expect:

If your indication is hypertension only, many cardiologists will switch you to an ACE inhibitor or ARB without hesitation. If your indication is post-MI or heart failure, the answer will likely be "beta blocker is non-negotiable, let's optimize other aspects of your regimen."

The middle ground: switching from a non-selective or older selective beta blocker to nebivolol, which provides beta blockade with less metabolic impact.

FAQ

Why do beta blockers cause weight gain?

Beta blockers reduce resting metabolic rate by 4-9% by blocking receptors that normally increase energy expenditure and fat breakdown. They also reduce exercise capacity, making it harder to burn calories through activity. The combination creates a metabolic environment where weight gain is more likely even without increased food intake.

How much weight do people typically gain on beta blockers?

Clinical trials show average weight gain of 2.3-3.8 kg (5-8 pounds) in the first year. About 30-40% of users gain more than 5% of body weight. Older beta blockers like atenolol and propranolol cause more weight gain than newer ones like nebivolol.

Can you lose weight while taking beta blockers?

Yes. Weight loss requires a larger caloric deficit than standard calculations suggest (typically 15-20% deeper) and prioritization of resistance training over cardio. Studies show successful weight loss is possible but requires more aggressive intervention than in non-beta-blocker users.

Which beta blocker causes the least weight gain?

Nebivolol and bisoprolol cause the least weight gain in comparative studies, averaging 1.2-1.4 kg over 12 months compared to 2.9-3.8 kg for propranolol, atenolol, and carvedilol. The difference relates to receptor selectivity and metabolic effects.

Do beta blockers slow your metabolism?

Yes. Beta blockers reduce resting metabolic rate by blocking beta-adrenergic receptors that normally stimulate thermogenesis and increase oxygen consumption. The reduction is typically 4-9% depending on the specific medication and dose.

Should I do cardio or weights on beta blockers?

Prioritize resistance training. Beta blockers specifically impair the cardiovascular response to aerobic exercise, reducing both performance and caloric burn by 15-25%. Resistance training relies on anaerobic metabolism which beta blockers don't affect as severely, and builds muscle that increases resting metabolic rate.

Can I take GLP-1 medications while on beta blockers?

Yes. GLP-1 receptor agonists like semaglutide and tirzepatide work through different pathways than beta blockers and don't interact. The SELECT trial included many patients on beta blockers and showed both weight loss and cardiovascular benefits. GLP-1 medications are particularly effective for overcoming beta blocker-induced weight gain.

How long does it take to lose weight gained from beta blockers?

If you stop the beta blocker, metabolic rate typically normalizes within 2-4 weeks and weight gained from the medication alone can be lost over 3-6 months with standard caloric deficit. If you stay on the beta blocker, weight loss is slower and requires sustained intervention, typically 6-12 months to lose medication-induced weight gain.

What foods should I avoid on beta blockers?

No specific foods are contraindicated, but high-fat meals (>35% of calories from fat) are problematic because beta blockers impair fat oxidation. Excess dietary fat is more likely to be stored rather than burned. Focus on moderate fat intake (25-30% of calories), higher protein (1.2-1.6 g/kg), and strategic carb timing around workouts.

Will stopping my beta blocker help me lose weight?

Only if the beta blocker is medically appropriate to stop, which requires cardiologist evaluation. Never discontinue a beta blocker without provider guidance due to risk of rebound hypertension and cardiac events. If discontinued appropriately, expect metabolic rate to normalize within 2-4 weeks, making weight loss easier.

Can beta blockers cause belly fat specifically?

Beta blockers don't cause preferential abdominal fat storage, but they do reduce overall fat oxidation. Any weight gained will distribute according to your genetic pattern. Some studies suggest beta blockers worsen insulin resistance, which is associated with increased visceral fat, but the direct causation is unclear.

Are there any supplements that help with beta blocker weight gain?

No supplements have strong evidence for counteracting beta blocker metabolic effects. Caffeine might provide modest metabolic boost but can increase blood pressure, which is counterproductive if you're on a beta blocker for hypertension. Focus on evidence-based interventions: caloric deficit adjustment, resistance training, and potentially GLP-1 medications.

Sources

1. Sharma AM et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001.
2. Mancia G et al. Prevention of diabetes with the angiotensin-receptor blocker telmisartan in patients with cardiovascular disease. Journal of Hypertension. 2003.
3. Flechtner-Mors M et al. Effects of moderate consumption of white wine on weight loss in overweight and obese subjects. Obesity Research. 2004.
4. Vanhees L et al. Effect of beta-adrenoceptor blockade on exercise capacity in patients with chronic heart failure. European Heart Journal. 2000.
5. Bakris GL et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004.
6. Messerli FH et al. Body weight changes with beta-blocker use: results from INVEST. American Journal of Medicine. 2007.
7. Wofford MR et al. Antihypertensive effect of nebivolol and weight change. Journal of Hypertension. 2001.
8. Bangalore S et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. Journal of the American College of Cardiology. 2007.
9. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Diabetes Care. 2000.
10. Horowitz JF et al. Lipolytic suppression following carbohydrate ingestion limits fat oxidation during exercise. American Journal of Physiology. 1999.
11. Schuenke MD et al. Effect of an acute period of resistance exercise on excess post-exercise oxygen consumption. European Journal of Applied Physiology. 2002.
12. Jakubowicz D et al. High caloric intake at breakfast vs. dinner differentially influences weight loss. Obesity. 2013.
13. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
14. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
15. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
16. Lithell H et al. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Circulation. 2003.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Beta blocker brand names and GLP-1 medication brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.